Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced the first prescription issuance for Tenapanor (trade name: Vteglea) in China, marking the commercial launch of the NHE3 inhibitor for serum phosphorus control in dialysis patients with chronic kidney disease (CKD). Licensed from Ardelyx, Inc. in December 2017, the drug received NMPA approval in February 2025 for patients with inadequate response or intolerance to phosphate binders, expanding Fosun’s nephrology portfolio into the hyperphosphatemia market serving China’s 400,000+ dialysis population.
Combination Studies: Tenapanor + binders vs. tenapanor monotherapy head-to-head data generation
Forward‑Looking Statements This brief contains forward‑looking statements regarding commercial launch performance, reimbursement negotiations, and market penetration for tenapanor in China. Actual results may differ due to competitive dynamics with phosphate binders, pricing regulations, and patient adoption patterns.-Fineline Info & Tech
Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.
